Meet
Chloé Chepigin

Chloé Chepigin supports clients with research and analysis spanning a variety of healthcare sectors and stakeholders.

She applies her background in drug pricing legislation, vaccine development, and health economics to advise a range of clients on diverse healthcare policy issues.

Prior to joining Avalere, Chloé supported the development of the World Health Organization’s National Assessment Tool for the Sustainable Local Production of Influenza Vaccines and produced the final progress report for the Global Action Plan for Influenza Vaccines. Additionally, she worked with the Office of Connecticut State Representative Sean Scanlon, where she collaborated with state legislators to develop bills concerning drug pricing transparency, access to essential health benefits, and value-based insurance design.

Chloé has an MPH from Yale School of Public Health and a BA in public health and international relations from the University of Rochester.

Authored Content


Vaccine development is at the forefront of global efforts to address the COVID-19 pandemic, with a rapidly growing pipeline of candidates that will expand the existing vaccine landscape.

The evolution of the US influenza vaccine market offers insights into the potential barriers and opportunities for successful rollouts of novel COVID-19 vaccines.

On April 15, President Trump announced his intention to halt funding to the World Health Organization (WHO), pending an investigation into WHO’s response to the COVID-19 pandemic. WHO first declared the outbreak a Public Health Emergency of International Concern on January 30 and a global pandemic on March 11. A reduction in funding from the US could limit WHO’s COVID-19 response activities as well as its regular vaccine programming, including product prequalification, global surveillance, and ongoing efforts to strengthen health systems.

Although influenza disease burden is high, vaccine uptake remains low.

Globally, the need to flatten the epidemic curve of COVID-19 cases has become the top public health priority to save lives and minimize the burden on the health care system. In the absence of treatments and prophylactics for the novel coronavirus, social distancing and quarantine strategies continue to be implemented in the US.

Opportunities exist to accelerate potential vaccine development.

On November 13, Avalere policy experts published a piece in the Health Affairs blog about considerations for developing and harmonizing HIV prevention recommendations to drive the goal of eliminating HIV.

We are extremely sorry for the technical difficulties that prevented us from streaming the webinar audio. We apologize to those who joined and were left waiting. We will reschedule the webinar as soon as possible. In the meantime, Richard, Alessandra, and Chloe are available to talk with each of you individually. Please look out for a new invite; we hope you can make it. Thank you for your patience and understanding.

Avalere experts recently presented “A Comprehensive Analysis of Influenza Vaccine Uptake in Medicare” at the National Adult and Influenza Immunization Summit in Atlanta, GA.

Nearly 80,000 people died during the 2017–2018 influenza season. Only 37% of adults were vaccinated. Several novel emerging products could make vaccination more accessible and effective, potentially reshaping the market and lowering influenza disease burden.